JP2018525445A5

JP2018525445A5 -

Info

Publication number: JP2018525445A5
Application number: JP2018528938A
Authority: JP
Filing date: 2016-08-22
Publication date: 2019-10-03
Anticipated expiration: 2036-08-22

Description

非イオン界面活性剤は他のものより変性作用が少ないため、タンパク質間相互作用を保持しながら膜タンパク質および脂質を可溶化するのに有用である。非イオン界面活性剤には、ポリエーテル系非イオン界面活性剤、ポリヒドロキシル系非イオン界面活性剤およびバイオ界面活性剤がある。非イオン界面活性剤としては、アルコールエトキシラート、アルキルフェノールエトキシラート、フェノールエトキシラート、アミドエトキシラート、グリセリドエトキシラート、脂肪酸エトキシラートおよび脂肪アミンエトキシラートが挙げられる。本明細書に開示される非イオン界面活性剤は、一般式Ｈ（ＯＣＨ_２ＣＨ_２）_ｘＯＣ_６Ｈ_４Ｒ^１、Ｈ（ＯＣＨ_２ＣＨ_２）_ｘＯＲ^２またはＨ（ＯＣＨ_２ＣＨ_２）_ｘＯＣ（Ｏ）Ｒ^２を有し得るものであり、式中、ｘはアルキルフェノールおよび／または脂肪アルコールもしくは脂肪酸に付加したエチレンオキシドのモル数を表し、Ｒ^１は長鎖アルキル基を表し、Ｒ^２は長鎖脂肪族基を表す。この実施形態の諸態様では、Ｒ^１がＣ_７〜Ｃ_１０アルキル基であり、かつ／またはＲ^２がＣ_１２〜Ｃ_２０脂肪族基である。その他の有用な非イオン界面活性剤としては、特に限定されないが、ＳＴＥＰＯＳＯＬ（登録商標）ＭＥＴ−１０Ｕ、メタセシスによって得られ不飽和短鎖アミドである非イオン界面活性剤を含めたバイオ非イオン界面活性剤が挙げられる。このようなバイオ界面活性剤は合成分子ではなく、植物などの有機物に由来する非イオン性のバイオ界面活性剤である。 Nonionic surfactants have less denaturing action than others and are useful for solubilizing membrane proteins and lipids while retaining protein-protein interactions. Nonionic surfactants include polyether-based nonionic surfactants, polyhydroxyl-based nonionic surfactants, and biosurfactants. Nonionic surfactants include alcohol ethoxylates, alkylphenol ethoxylates, phenol ethoxylates, amido ethoxylates, glyceride ethoxylates, fatty acid ethoxylates and fatty amine ethoxylates. The nonionic surfactants disclosed herein have the general formula H (OCH ₂ CH ₂ ) _x OC ₆ H ₄ R ¹ , H (OCH ₂ CH ₂ ) _x OR ² or H (OCH ₂ CH ₂ ) _x OC (O) R ² where x represents the number of moles of ethylene oxide added to the alkylphenol and / or fatty alcohol or fatty acid, R ¹ represents a long chain alkyl group, and R ² represents Represents a long chain aliphatic group. In aspects of this embodiment, R ¹ is a C ₇ -C ₁₀ alkyl group and / or R ² is a C ₁₂ -C ₂₀ aliphatic group. Other useful nonionic surfactants include, but are not limited to, STEPOLSOL® MET-10U, bio nonionic surfactants including nonionic surfactants that are unsaturated short chain amides obtained by metathesis Agents. Such a biosurfactant is not a synthetic molecule but a nonionic biosurfactant derived from organic substances such as plants.

Claims

A method for controlling pathogens of plant diseases,
The method includes applying an effective amount of a botanical pharmaceutical composition to one or more plants parasitized with a pathogen and / or one or more such that the pathogen is exposed to the botanical pharmaceutical composition. Applying an effective amount of a botanical pharmaceutical composition to the location of the plant, wherein the application of the botanical pharmaceutical composition has a detrimental effect on the pathogen to be controlled,
It said plant for pharmaceutical composition comprises a treated fermenting microorganism supernatant and one or more nonionic surface active agents, free of active enzyme, 5. Having a pH of less than 0,
Way .

  A method for increasing plant growth and / or crop production comprising:
  The method includes applying an effective amount of a botanical pharmaceutical composition to one or more plants and / or at one or more locations that expose the one or more plants to the botanical pharmaceutical composition. Applying an effective amount of a botanical pharmaceutical composition, the application of the botanical pharmaceutical composition improves absorption by root hair, improves xylem sap flow through the xylem, and photosynthetic product flow in the phloem , Improved absorption of water, minerals and other nutrients from the soil, increased capillary action and / or hydrostatic pressure in the xylem, and / or increased synthesis of compounds and energy, and / or xylem sap flow And / or destruction of one or more components that inhibit photosynthetic product flow,
  The botanical pharmaceutical composition comprises a treated fermented microbial supernatant and one or more nonionic surfactants, no active enzyme, and a pH of less than 5.0,
Method.

  A method of maintaining or improving the efficiency of an irrigation system,
  The method includes applying an effective amount of a botanical drug composition to one or more pipes in a pipeline network of the irrigation system, the application of the botanical drug composition to the one or more pipes. One or more components that block the pipes are sufficiently removed,
  The botanical pharmaceutical composition comprises a treated fermented microbial supernatant and one or more nonionic surfactants, no active enzyme, and a pH of less than 5.0,
Method.

The method according to any one of claims 1 to 3, wherein the treated fermentation microorganism supernatant is derived from a fermentation yeast supernatant, a fermentation bacteria supernatant, a fermentation mold supernatant, or any combination thereof.

The fermented yeast supernatant is genus Brettanomyces, Candida, Cyberlindera, Cystofilobasidium, Debaryomykes, and Debaryomykes. Fusarium, Geotrichum, Issachchenkia, Kazachstania, Kloeckera, Nluyc, Lluicor ), Pedioco Pediococcus, Penicillium, Pichia, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Saccharomyces Schizosaccharomyces), preparative Rikosuporon genus (Thrichosporon), Torulaspora genus (Torulaspora), Torulopsis (Torulopsis), Verticillium genus (Verticillium), Yarrowia (Yarrowia), Gigot Saccharomyces (Zygosaccharomyces) or post Torulaspora genus (Zygotorulaspor It is obtained from the yeast species belonging to) The method of claim 4.

The method according to claim 5 , wherein the fermentation yeast supernatant is obtained from the yeast Saccharomyces cerevisiae.

7. The method of any one of claims 1-6, wherein the botanical pharmaceutical composition comprises from about 5 wt% to about 95 wt% treated fermented microbial supernatant.

It said plant for pharmaceutical compositions comprising said processed fermented microbial supernatant at least 35 wt% A method according to any one of claims 1-7.

The method according to any one of claims 1 to 8 , wherein the plant pharmaceutical composition comprises a maximum of 90 % by weight of the treated fermented microorganism supernatant.

The method according to any one of claims 1 to 9 , wherein the nonionic surfactant comprises a polyether-based nonionic surfactant, a polyhydroxyl-based nonionic surfactant, and / or a biosurfactant.

The polyhydroxyl nonionic surfactant comprises sucrose ester, ethoxylated sucrose ester, sorbital ester, ethoxylated sorbital ester, alkyl glucoside, ethoxylated alkyl glucoside, polyglycerol ester or ethoxylated polyglycerol ester. Item 11. The method according to Item 10 .

The nonionic surfactant is amine oxide, ethoxylated alcohol, ethoxylated fatty alcohol, alkylamine, ethoxylated alkylamine, ethoxylated alkylphenol, alkyl polysaccharide, ethoxylated alkyl polysaccharide, ethoxylated fatty acid, ethoxylated fat. Alcohols or ethoxylated fatty amines, or the general formula H (OCH ₂ CH ₂ ) _x OC ₆ H ₄ R ¹ , H (OCH ₂ CH ₂ ) _x OR ² or H (OCH ₂ CH ₂ ) _x OC (O) R ² a non-ionic surfactant have a, wherein, x is from, represents the number of moles of ethylene oxide added to alkylphenols and / or fatty alcohol or fatty acid, R ¹ represents a long chain alkyl group, R ² is nonionic surfactant representative of the long-chain aliphatic group, a containing A method according to any one of claims 1 to 11.

R ¹ is Ru _C 7 _{-C 10} normal alkyl groups der, and / or ^{R 2} is a _C 12 _{-C 20} aliphatic group, The method of claim 12.

The nonionic surfactant is ethoxylated nonylphenol, ethoxylated octylphenol, ethoxylated cet-oleyl alcohol, ethoxylated cet-stearyl alcohol, ethoxylated decyl alcohol, ethoxylated dodecyl alcohol, ethoxylated tridecyl alcohol or ethoxylated castor oil in a method according to any one of claims 1 to 13.

It said plant for pharmaceutical compositions, wherein comprising one or more non-ionic surfactants from about 1% to about 15 wt% A method according to any one of claims 1-14.

16. The method of claim 15 , wherein the botanical pharmaceutical composition comprises about 5% to about 13% by weight of the one or more nonionic surfactants.

17. The method of claim 16 , wherein the botanical pharmaceutical composition comprises about 7% to about 11% by weight of the one or more nonionic surfactants.

The plant for the pharmaceutical composition further comprises one or more anionic surfactants, method according to any one of claims 1 to 17.

19. The method of claim 18 , wherein the botanical pharmaceutical composition comprises from about 0.5% to about 10% by weight of the one or more anionic surfactants.

20. The method of claim 19 , wherein the botanical pharmaceutical composition comprises about 1 wt% to about 8 wt% of the one or more anionic surfactants.

21. The method of claim 20 , wherein the botanical pharmaceutical composition comprises about 2% to about 6% by weight of the one or more anionic surfactants.

The pH is maximum 4.5 A method according to any one of claims 1 to 21.

24. The method of claim 22 , wherein the pH is from about 3.7 to about 4.2.

24. The method according to any one of claims 1 to 23 , wherein the botanical pharmaceutical composition further comprises an antimicrobial agent.

25. The method according to any one of claims 1 to 24 , wherein the botanical pharmaceutical composition consists only of components that are substantially non-toxic to humans, mammals, plants and the environment.

26. The method according to any one of claims 1 to 25 , wherein the botanical pharmaceutical composition is composed only of components that are biodegradable.

27. The application of the botanical pharmaceutical composition forms a plurality of microbubbles having highly reactive shells that enhance gas mass transfer and promote biocatalytic activity of the compound. The method according to item.